Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation – The UMBRELLA Cohort

Overview

Due to better treatment options and earlier detection, survival rates of patients with breast cancer continue to increase. As such, (late) treatment toxicity, (long-term) quality of life and the cosmetic outcome are becoming more important. Also, many competing experimental interventions (e.g. treatment, lifestyle interventions) for breast cancer are being developed, all in need to be properly evaluated before being implemented in routine clinical care. Randomized Controlled Trials are the gold standard to do so, but they have shown many challenges, especially when applied in a cancer setting. The 'cohort multiple Randomized Controlled Trial (cmRCT)' design is a promising design for multiple (simultaneous) randomized evaluations of experimental interventions, with potential for increased recruitment, comparability and long-term outcomes as a standard.

By setting up UMBRELLA, as a prospective cohort according to the cmRCT design, the investigators aim to:

- provide an infrastructure for efficient, fast and pragmatic evaluation and implementation of experimental interventions

- gain insight into short and long-term treatment response, toxicity, complications, quality of life and survival of patients with breast cancer.

Full Title of Study: “Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation – The UMBRELLA Cohort”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2053

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline Quality of Life at 10 years
    • Time Frame: 10 years
    • Assesment of Health-related quality of life in breast cancer patients undergoing radiation

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years
  • Patients with breast cancer who undergo irradiation in the UMC Utrecht
  • Informed consent – at least – for use of routinely collected clinical data and to fill out questionnaires.

Exclusion Criteria

  • Inability to understand the Dutch language

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • UMC Utrecht
  • Provider of Information About this Clinical Study
    • Principal Investigator: Helena M Verkooijen, Associate Professor – UMC Utrecht
  • Overall Official(s)
    • Helena M Verkooijen, MD, PhD, Principal Investigator, UMC Utrecht
  • Overall Contact(s)
    • Helena M Verkooijen, MD, PhD, h.m.verkooijen@umcutrecht.nl

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.